Since inception of the Cardiovascular Data Analysis Center (CDAC) in 1993, our Institute has been recognized as one of the world leaders within the interventional cardiology arena. Today, Baim’s expertise remains rooted in the cath lab where this tradition continues to keep us at the forefront of new device innovation. This experience has ranged from late generations of bare metal stents, the first generation of drug-eluting stents, through to the introduction of left ventricular assist and structural heart devices. With our Faculty consisting of active clinicians, we are able to provide a valuable perspective on how devices will be received in cath labs and by regulatory agencies around the globe.
Cardiometabolic Syndrome (CMS) represents one of the most prevalent threats to public health that exists today. Cardiometabolic syndrome is a clustering of interrelated risk factors that promote the development of atherosclerotic vascular disease and type 2 diabetes mellitus. These risk factors have a direct effect on atherogenic dyslipidemia, elevated blood pressure, and elevated plasma glucose, and promote proinflammatory and prothrombic states.
The Baim Institute’s focus on cardiometabolic research encompasses trials in lipids, heart failure, diabetes, and nephrology. Our efforts in this area are led by Christopher Cannon, MD, a world-renown cardiologist and professor at Harvard Medical School. Jim Januzzi, MD, spearheads Baim’s heart failure research initiative.
As a leading Academic Research Organization, The Baim Institute offers several competitive advantages in the area of high-quality clinical event adjudication, valuable scientific leadership, and operational excellence. Under the leadership of Dr. Donald Cutlip, a recognized leader in the definition and adjudication of cardiac events, The Baim has established an active CEC that is supported by a team of highly skilled Clinical Reviewers.
In addition to Dr. Cutlip, The Baim’s CEC membership roster is comprised of board-certified physicians with an average of eight years of CEC experience. Each CEC member has been vetted for confidentiality and conflict of interest issues and all members are active clinicians in their respective fields of specialty, which includes both teaching and publishing.
Operationally, The Baim has implemented a cutting-edge data collection process, which has been used to streamline source document collection. Utilizing Lean Methodology, The Baim has been able to reduce the lead time for adjudication by over 30%. The integration of electronic data collection methods along with an extensive quality control process is what makes The Baim adjudication process the industry gold standard. As a result of The Baim’s scalable process, our experienced team has adjudicated more than 60,000 events over the last 10 years.
Two essential facets of clinical research are patient-centered outcomes and cost-effectiveness of treatments. Baim’s Economics and Quality of Life group provides expert trial design, biostatistics, and diligent follow-up of patients in clinical studies. The EQoL group is led by a board-certified clinical cardiac electrophysiologist, Dr. Matthew Reynolds of Tufts Medical School and the Lahey Clinic Medical Center, who is trained in outcomes research, including health economics and quality of life. This group provides the necessary expertise to analyze both the patient-centered and financial impacts of investigational and approved treatments.
Led by Dr. James Januzzi, a world leader in cardiovascular biomarker research, one of The Baim’s core areas of focus is biomarker and diagnostics clinical studies. Specifically in the area of heart failure, cardiovascular biomarkers are becoming an invaluable guide to the treatment of the disease. These biomarkers are of course, not limited to just heart failure. The Baim applies the same academic model as our other Centers of Excellence, integrating Faculty expertise into study operations to investigate the benefits of select biomarkers and the diagnostic tools to measure them.